Texas Top Legal Officer Sues Acetaminophen Manufacturers Concerning Autism Spectrum Allegations

Courtroom Case
The Texas Attorney General, who supports former President Trump campaigning for the United States Senate, alleged pharmaceutical manufacturers of hiding safety concerns of acetaminophen

Texas Attorney General Ken Paxton is filing a lawsuit against the makers of Tylenol, claiming the firms withheld potential risks that the drug created to pediatric neurological development.

The court filing follows thirty days after Former President Trump promoted an unverified association between using acetaminophen - referred to as acetaminophen - while pregnant and autism in young ones.

Paxton is suing Johnson & Johnson, which once produced the drug, the only pain reliever recommended for expectant mothers, and Kenvue, which currently produces it.

In a statement, he claimed they "misled consumers by profiting off of pain and marketing drugs ignoring the risks."

The company asserts there is no credible evidence connecting acetaminophen to autism spectrum disorder.

"These companies lied for decades, deliberately risking millions to boost earnings," the attorney general, a Republican, said.

The manufacturer said in a statement that it was "very worried by the perpetuation of misinformation on the safety of acetaminophen and the likely effects that could have on the health of US mothers and children."

On its online platform, Kenvue also mentioned it had "regularly reviewed the pertinent research and there is insufficient valid information that demonstrates a established connection between consuming paracetamol and autism."

Organizations acting on behalf of physicians and health professionals agree.

The leading OB-GYN organization has stated acetaminophen - the main ingredient in acetaminophen - is among limited choices for expectant mothers to treat discomfort and fever, which can present major wellness concerns if left untreated.

"In multiple decades of research on the consumption of paracetamol in pregnancy, zero credible investigations has conclusively proven that the consumption of paracetamol in any period of gestation leads to brain development issues in offspring," the group stated.

The lawsuit references recent announcements from the Trump administration in arguing the medication is allegedly unsafe.

In recent weeks, the former president generated worry from health experts when he instructed pregnant women to "resist strongly" not to consume acetaminophen when unwell.

The FDA then issued a notice that medical professionals should consider limiting the use of Tylenol, while also stating that "a direct connection" between the medication and autism spectrum disorder in children has remains unverified.

The Health Department head RFK Jr, who oversees the Food and Drug Administration, had promised in April to initiate "extensive scientific investigation" that would establish the cause of autism spectrum disorder in a matter of months.

But experts cautioned that discovering a unique factor of autism - believed by scientists to be the consequence of a intricate combination of inherited and external influences - would be difficult.

Autism is a type of permanent neurological difference and disability that affects how individuals perceive and interact with the environment, and is identified using physician assessments.

In his court filing, Paxton - a Trump ally who is campaigning for US Senate - asserts Kenvue and J&J "willfully ignored and sought to suppress the science" around acetaminophen and autism spectrum disorder.

The lawsuit aims to force the companies "remove any commercial messaging" that asserts Tylenol is safe for pregnant women.

The court case parallels the concerns of a group of mothers and fathers of minors with autism spectrum disorder and ADHD who sued the manufacturers of Tylenol in 2022.

A federal judge dismissed the case, stating studies from the parents' expert witnesses was lacking definitive proof.

Amanda Lee
Amanda Lee

A tech enthusiast and writer passionate about innovation and self-improvement, sharing experiences and knowledge.